Compugen (CGEN) CFO David Silberman Receives RSUs & Option

What Happened
David Silberman, Chief Financial Officer of Compugen Ltd. (CGEN), received equity awards on July 29, 2026: 19,500 restricted stock units (RSUs) and a 26,000-share derivative award (an option). Both awards were reported as acquired at $0.00 (typical for grants); the filing does not state a cash value or fair-market valuation in this Form 4. These are grants/awards (not open-market purchases or sales).

Key Details

• Transaction date: 2026-07-29; Form 4 filed 2026-07-30 (appears timely).
• Awards: 19,500 RSUs (F1) and 26,000-share option/derivative (F2). Reported acquisition price: $0.00.
• Shares owned after transaction: not specified in the provided filing excerpt.
• Vesting (per footnotes): both awards vest 25% on September 30, 2027, with the remainder vesting in 12 equal quarterly installments thereafter, subject to continued service.
• No exercise, sale, tax-withholding event, or 10b5-1 plan is reported here—these are standard grants, not exercises or dispositions.

Context

• The 26,000-share item is a derivative (an option) that vests over time; it has not been exercised and no shares were sold in this filing.
• Grants like RSUs/options compensate and retain executives and do not by themselves indicate immediate insider sentiment—economic benefit is realized only as awards vest (and, for options, if exercised).
• Filing timing (filed the next day) suggests the report was submitted promptly.